Ding, X <br/><br/>
Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS.  [electronic resource] 

 -  Journal of pharmaceutical and biomedical analysis  Jul 2016 
 - 117-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Validation Study 
<br/><br/><label>ISSN: </label>1873-264X 
<br/><br/><label>Standard No.: </label>10.1016/j.jpba.2016.04.030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--analysis<br/>Area Under Curve<br/>Calibration<br/>Chromatography, Liquid--methods<br/>Chromatography, Reverse-Phase--methods<br/>Drug Stability<br/>Drug Storage<br/>Half-Life<br/>Humans<br/>Imidazoles--analysis<br/>Linear Models<br/>Oxazepines--analysis<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Reproducibility of Results<br/>Solid Phase Extraction--methods<br/>Tandem Mass Spectrometry--methods<br/>Temperature<br/>Time Factors